These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 12921800)
1. Vasopeptidase inhibitors for heart failure: where do we go from here? Richards AM Eur J Heart Fail; 2003 Aug; 5(4):411-3. PubMed ID: 12921800 [No Abstract] [Full Text] [Related]
2. Vasopeptidase inhibition in heart failure. van Veldhuisen DJ; van Gilst WH Lancet; 2000 Oct; 356(9240):1526. PubMed ID: 11081561 [No Abstract] [Full Text] [Related]
4. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? Teerlink JR J Card Fail; 2002 Jun; 8(3):124-7. PubMed ID: 12140803 [No Abstract] [Full Text] [Related]
5. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA; Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927 [TBL] [Abstract][Full Text] [Related]
6. [Vasopeptidase inhibitors. Omapatrilat in hypertension and heart failure]. Heinzl S Med Monatsschr Pharm; 2000 Feb; 23(2):38-41. PubMed ID: 10701306 [No Abstract] [Full Text] [Related]
7. [Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure]. Latini R Ital Heart J Suppl; 2001 Jan; 2(1):83-4. PubMed ID: 11216088 [No Abstract] [Full Text] [Related]
9. [Omapatrilat for treatment of heart failure]. Yamazaki T Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381 [No Abstract] [Full Text] [Related]
10. [The new class of drugs-- metalloprotease inhibitors -- in the treatment of heart failure]. Berezin AE Klin Med (Mosk); 2004; 82(5):7-15. PubMed ID: 15230033 [No Abstract] [Full Text] [Related]
11. Omapatrilat for the management of heart failure and hypertension. Husereau DR Issues Emerg Health Technol; 2001 Jun; (17):1-4. PubMed ID: 11776285 [TBL] [Abstract][Full Text] [Related]
12. Vasopeptidase inhibitors--concepts and evidence. Ruschitzka F; Corti R; Quaschning T; Hermann M; Lüscher TF Nephrol Dial Transplant; 2001 Aug; 16(8):1532-5. PubMed ID: 11477147 [No Abstract] [Full Text] [Related]
14. Vasopeptidase inhibitors: a bradykinin link. Boix F Lancet; 2002 Mar; 359(9312):1157-8. PubMed ID: 11943297 [No Abstract] [Full Text] [Related]
15. Omapatrilat may indeed not be much superior (OMINOUS). Cheng TO Int J Cardiol; 2003 Sep; 91(1):113. PubMed ID: 12957741 [No Abstract] [Full Text] [Related]
16. Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure. Witte K; Thackray S; Banerjee T; Clark AL; Cleland JG Eur J Heart Fail; 2000 Mar; 2(1):107-12. PubMed ID: 10742710 [TBL] [Abstract][Full Text] [Related]
18. Omapatrilat: a unique new agent for the treatment of cardiovascular disease. Nawarskas JJ; Anderson JR Heart Dis; 2000; 2(3):266-74. PubMed ID: 11728268 [TBL] [Abstract][Full Text] [Related]
19. Vasopeptidase inhibitors: potential role in the treatment of heart failure. Trindade PT; Rouleau JL Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892 [TBL] [Abstract][Full Text] [Related]